103 related articles for article (PubMed ID: 23138354)
1. Effects of thirty-times chewing per bite on secretion of glucagon-like peptide-1 in healthy volunteers and type 2 diabetic patients.
Sonoki K; Iwase M; Takata Y; Nakamoto T; Masaki C; Hosokawa R; Murakami S; Chiwata K; Inoue H
Endocr J; 2013; 60(3):311-9. PubMed ID: 23138354
[TBL] [Abstract][Full Text] [Related]
2. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
[TBL] [Abstract][Full Text] [Related]
3. Increased chewing reduces energy intake, but not postprandial glucose and insulin, in healthy weight and overweight young adults.
Borvornparadorn M; Sapampai V; Champakerdsap C; Kurupakorn W; Sapwarobol S
Nutr Diet; 2019 Feb; 76(1):89-94. PubMed ID: 29767425
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
[TBL] [Abstract][Full Text] [Related]
5. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
Toft-Nielsen MB; Madsbad S; Holst JJ
Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion.
Hagemann D; Holst JJ; Gethmann A; Banasch M; Schmidt WE; Meier JJ
Regul Pept; 2007 Oct; 143(1-3):64-8. PubMed ID: 17434608
[TBL] [Abstract][Full Text] [Related]
7. Improvement in chewing activity reduces energy intake in one meal and modulates plasma gut hormone concentrations in obese and lean young Chinese men.
Li J; Zhang N; Hu L; Li Z; Li R; Li C; Wang S
Am J Clin Nutr; 2011 Sep; 94(3):709-16. PubMed ID: 21775556
[TBL] [Abstract][Full Text] [Related]
8. Venous blood provides lower glucagon-like peptide-1 concentrations than arterialized blood in the postprandial but not the fasted state: Consequences of sampling methods.
Chen YC; Edinburgh RM; Hengist A; Smith HA; Walhin JP; Betts JA; Thompson D; Gonzalez JT
Exp Physiol; 2018 Sep; 103(9):1200-1205. PubMed ID: 29947441
[TBL] [Abstract][Full Text] [Related]
9. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
[TBL] [Abstract][Full Text] [Related]
10. Effects of thorough mastication on postprandial plasma glucose concentrations in nonobese Japanese subjects.
Suzuki H; Fukushima M; Okamoto S; Takahashi O; Shimbo T; Kurose T; Yamada Y; Inagaki N; Seino Y; Fukui T
Metabolism; 2005 Dec; 54(12):1593-9. PubMed ID: 16311091
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.
Ritzel R; Schulte M; Pørksen N; Nauck MS; Holst JJ; Juhl C; März W; Schmitz O; Schmiegel WH; Nauck MA
Diabetes; 2001 Apr; 50(4):776-84. PubMed ID: 11289042
[TBL] [Abstract][Full Text] [Related]
12. Impact of exogenous hyperglucagonemia on postprandial concentrations of gastric inhibitory polypeptide and glucagon-like peptide-1 in humans.
Meier JJ; Ritter PR; Jacob A; Menge BA; Deacon CF; Schmidt WE; Nauck MA; Holst JJ
J Clin Endocrinol Metab; 2010 Aug; 95(8):4061-5. PubMed ID: 20501678
[TBL] [Abstract][Full Text] [Related]
13. The effect of gum chewing on blood GLP-1 concentration in fasted, healthy, non-obese men.
Xu J; Xiao X; Li Y; Zheng J; Li W; Zhang Q; Wang Z
Endocrine; 2015 Sep; 50(1):93-8. PubMed ID: 25758865
[TBL] [Abstract][Full Text] [Related]
14. Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial.
Kuwata H; Iwasaki M; Shimizu S; Minami K; Maeda H; Seino S; Nakada K; Nosaka C; Murotani K; Kurose T; Seino Y; Yabe D
Diabetologia; 2016 Mar; 59(3):453-61. PubMed ID: 26704625
[TBL] [Abstract][Full Text] [Related]
15. COMPARISON OF THE LEVELS OF C-REACTIVE PROTEIN, GLP-1 AND GLP-2 AMONG INDIVIDUALS WITH DIABETES, MORBID OBESITY AND HEALTHY CONTROLS: AN EXPLORATORY STUDY.
Cazzo E; Pareja JC; Chaim EA; Coy CSR; Magro DO
Arq Gastroenterol; 2018; 55(1):72-77. PubMed ID: 29561982
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
[TBL] [Abstract][Full Text] [Related]
17. Ghrelin Impairs Prandial Glucose Tolerance and Insulin Secretion in Healthy Humans Despite Increasing GLP-1.
Tong J; Davis HW; Gastaldelli A; D'Alessio D
J Clin Endocrinol Metab; 2016 Jun; 101(6):2405-14. PubMed ID: 27055279
[TBL] [Abstract][Full Text] [Related]
18. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.
Salehi M; Aulinger B; Prigeon RL; D'Alessio DA
Diabetes; 2010 Jun; 59(6):1330-7. PubMed ID: 20215429
[TBL] [Abstract][Full Text] [Related]
19. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
Cuthbertson J; Patterson S; O'Harte FP; Bell PM
Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
[TBL] [Abstract][Full Text] [Related]
20. [The changes of gastrointestinal hormones GLP-1, PYY and ghrelin in patients with newly diagnosed type 2 diabetes mellitus].
Cui T; Ren Y; Ma H; Liu SF; Zhang XX; Yu HL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 44(5):774-8. PubMed ID: 24325110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
